Portal Hypertensive Gastropathy (PHG) by Gamie, Samia Ali
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 5
Portal Hypertensive Gastropathy (PHG)
Samia Ali Gamie
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.69539
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Samia Ali Gamie
Additional information is available at the end of the chapter
Abstract
Reversal of erosive gastritis in patients with portal hypertension by surgical shunts 
evolves the term of portal hypertensive gastropathy. In 1984, Sarfeh et al. addressed the 
term PHG to describe the distinctive erosive gastritis in patients with portal hyperten‐
sion. Since that time, the recorded incidence of PHG in the studies has varied widely 
from 20 to 75% in patients with portal hypertension, with or without liver cirrhosis. As 
the underlying pathophysiology of the disease is unclear, not all the patients with por‐
tal hypertension developed PHG. Thus, portal hypertension cannot be the only factor 
for the development of PHG. Patients with PHG presented with either acute or chronic 
bleedings. Acute presentation is an emergency case. Anemia from chronic bleeding is a 
frequent presentation in PHG patients. The diagnosis is confirmed by a characteristic 
endoscopic appearance of PHG. Capsule endoscopy and dynamic CT are also used for 
the diagnosis of PHG. The goal of the treatment of PHG is reducing the portal pres‐
sure in patients with acute or chronic bleeding. Pharmacological treatment, endoscopic 
therapy, trans‐jugular intrahepatic portosystemic shunt (TIPS), and shunt surgery are 
different modalities for treatment of PHG. Yet, primary prophylaxis treatment is not rec‐
ommended in the patients with PHG.
Keywords: portal hypertensive gastropathy, portal hypertension, gastropathy, GAVE, 
liver cirrhosis
1. Introduction
1.1. Definition
Portal hypertensive gastropathy (PHG) is a painless condition of gastric mucosal ectasia and 
impaired mucosal defense, typically seen in patients with portal hypertension [1].
Portal hypertension (PH) exists when the hydrostatic pressure in the portal vein or its 
branches has increased. Two important factors are implicated; vascular resistance and 
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blood flow, thus if the pressure gradient anywhere along the portal venous system 
(between the portal vein, and hepatic veins or the inferior vena cava (IVC)) is increased, 
portal hypertension develops.
The normal portal venous pressure ranges from 5 to 10 mm Hg, therefore, if the hepatic 
venous pressure gradient (HVPG) is ≥10 mm Hg, significant portal hypertension is consid‐
ered, but if the HVPG is ≥12 mm Hg, severe portal hypertension is diagnosed [2].
The causes of portal hypertension are classified into three categories related to anatomical 
consideration. First, are causes originating in the portal venous system before it reaches the 
liver (pre‐hepatic), e.g. portal vein thrombosis, schistosomiasis, primary biliary cholangi‐
tis/primary sclerosing cholangitis, or congenital hepatic fibrosis. Second, are causes within 
the liver (intrahepatic) e.g. cirrhosis as a result of viral, non alcoholic fatty liver disease 
(NAFLD), or autoimmune. Finally, are causes between the liver and the heart (post‐hepatic) 
e.g. Budd‐Chiari syndrome, inferior vena cava obstruction, or hepatic veno‐occlusive dis‐
ease (Table 1). The most common cause of PH is cirrhosis [3].
1.2. Essentials to diagnose PHG
• Portal hypertension with or without cirrhosis.
• Characteristic endoscopic findings.
Prehepatic Hepatic Posthepatic
Portal vein thrombosis Cirrhosis of any cause, e.g. chronic viral hepatitis, 
alcoholic, autoimmune, NAFLD, biliary atresia, etc.
Inferior vena cava obstruction
Arteriovenous fistula Primary biliary cholangitis Hepatic vein thrombosis
Splenomegaly Primary sclerosing cholangitis Budd‐Chiari syndrome
Schistosomiasis Right sided heart failure, e.g. from 
constrictive pericarditis
Congenital hepatic fibrosis
Nodular regeneration hyperplasia
Granulomatous or infiltrative diseases (Gaucher, 
sarcoidosis, amyloid deposition
Toxicity (from arsenic, copper, methotrexate, 
amiodarone, ….)
Veno‐occlusive disease
NAFLD, non alcoholic fatty liver disease.
Table 1. Condition associated with portal hypertension.
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2. History
In 1984, Sarfeh et al. recognized a distinct form of gastric mucosal hemorrhage in patients who had 
portal hypertension, they called it “portal hypertensive gastritis”. They reported that this mucosal 
lesion in patients with portal hypertension was reversed after the portacaval shunt, in contrary to 
the mucosal lesion of patients without portal hypertension. Therefore, they concluded that there 
is a unique mucosal change excited with portal hypertension. 1 year later, it was discovered that 
this mucosal change was not a form of gastritis as there is no evidence of inflammation in the 
mucosa. Specific histopathological findings described this change, and the term “portal hyper‐
tensive gastropathy” was introduced by McCormack et al. in 1985 as a separate entity. However, 
there was no grading system of the endoscopic findings to put an accurate score for this condition. 
Several grading systems like the three‐ category system, and the two‐category system have been 
proposed in 1994. The clinical importance of grading classification system resides in the fact that 
patients with severe PHG have a higher chance to bleed than patients with mild PHG [4].
The overall mortality from gastrointestinal bleeding is up to 25% of the mortality in patients 
with cirrhosis. In recent years however, PHG has been recognized as a distinct entity of 
gastrointestinal bleeding in patients with cirrhosis and portal hypertension. While variceal 
hemorrhage and peptic ulcer disease are known as significant causes of GI bleeding in cir‐
rhosis, PHG and gastric antral vascular ectasia (GAVE) should also be considered as impor‐
tant causes. However, PHG should be differentiated from GAVE, GAVE occurs in patients 
with cirrhosis and portal hypertension, in addition to other conditions, such as chronic renal 
failure, connective tissue disorders, and bone marrow transplantation. On the other hand, 
PHG occurs only in patients with portal hypertension, whether with or without cirrhosis. In 
patients with cirrhosis, PHG is more common than GAVE [5].
However, although the endoscopic, histological and hemodynamic features of PHG mucosa 
have been extensively studied, the pathogenesis of PHG is still poorly understood, its natural 
history is not clearly documented and its treatment needs to be improved [6].
3. Epidemiology
The incidence of PHG varies greatly, it ranges between 20 and 75% of patients with portal hyper‐
tension, of those, approximately 65–90% have mild PHG, whereas 10–25% have severe PHG. 
This wide discrepancy in results may be attributed to the fact that the study was carried out on 
different groups of patients; patients with cirrhosis, patients without cirrhosis, patients with dif‐
ferent Child‐Pugh score of liver failure, and lastly patients with history of previous esophageal 
eradication therapy [7]. It was noticed that higher prevalence of PHG is found in patients with 
severe portal hypertension, advanced liver disease, and post‐eradication therapy of esophageal 
varices [8]. Conversely, the incidence of acute gastrointestinal bleeding (hematemesis and/or 
melena) in PHG patients with cirrhosis were low; reported incidences ranged from 2.5 to 30%, 
with the greatest occurrences being observed in patients with severe PHG [9].
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On the other hand, PHG as a marker of portal hypertension has conflicting results among the 
studies. Its sensitivity, positive predictive value (PPV) and negative predictive value (NPV), 
vary considerably between the studies, but its specificity has been reported to be above 95%. 
Snake‐skin pattern has higher specificity (93–100%) for the diagnosis of PHG [10].
PHG can present at any age, including pediatric or adult patients [7].
4. Pathophysiology
The pathogenesis of PHG is still poorly understood. Portal hypertension is essential in the 
presence of PHG, due to the mechanical effect of the increased pressure in the portal vein 
which leads to hyper‐dynamic congestion with a net increase in the gastric blood flow, this 
increase occurs in the submucosal, muscle, and serosal layers, while decreasing in the muco‐
sal layer due to congestion and stasis. These hemodynamic changes impair gastric muco‐
sal defense mechanisms, which lead to release of pro‐inflammatory mediators, and alter the 
growth factors which render gastric mucosa more susceptible to injury, and impair mucosal 
healing. This defenseless mucosa may explain the increase in the rate of bleeding from PHG, 
additionally this abnormal gastric microcirculation, may render gastric mucosa more vulnera‐
ble to hypoxia, and more susceptible to noxious gastric factors, such as aspirin and ethanol [4].
Many other factors have also been implicated in the pathogenesis of PHG such as increased pro‐
duction of nitric oxide (NO), oxygen free radicals, endothelin‐1, tumor necrosis factor‐α, and 
prostaglandins. The most important factor, NO, is a potent vasodilator secreted by endothelial 
cells which may underlie the gastric vascular dilation and hyper‐dynamic circulation in PHG. 
Furthermore, the expression of transforming growth factor α (TGF‐α) and the epidermal growth 
factor (EGF) receptors in the gastric mucosa were reported to be highly elevated in areas of spon‐
taneous gastric injury. Recently, studies found other factors, like p53‐upregulated modulator of 
apoptosis (PUMA), to be markedly induced in the gastric mucosa of PHG patients [11]. Increased 
gastric mucosal apoptosis and decreased mucosal proliferation, were also noted in rats with PGH.
5. Factors influencing the development of portal hypertensive gastropathy
Many factors related to portal hypertension affect the presence and the severity of PHG. As 
the commonest cause of portal hypertension is liver cirrhosis, the presence or absence of 
 cirrhosis, and its severity, may also affect the PHG.
5.1. Factors related to portal hypertension
• Severity of portal hypertension: The frequency of PHG is strongly correlated with the 
severity of portal hypertension, as indicated by hepatic venous pressure gradient (HVPG), 
esophageal intra‐variceal pressure, and/or presence of esophageal varices and its size [12]. 
It was also found that portal hypertension associates with severe PHG, but not mild PHG, 
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this was evident in patients with severe PHG, which were discovered to have elevated 
HVPG, high hepatic sinusoidal resistance, and low hepatic blood flow, all markers of se‐
vere portal hypertension [12].
This leads us to the conclusion that not all patients with portal hypertension exhibit evi‐
dence of, or develop PHG. On the other hand, resolution of PHG, which occurs after inter‐
vention to decrease portal hypertension (by pharmacotherapy, trans‐jugular intrahepatic 
portosystemic shunt (TIPS), or liver transplantation), may suggest an association between 
PHG and portal hypertension [13].
Thus, although PHG cannot be diagnosed without portal hypertension, it is however not 
the only factor that evokes PHG.
• Correlation with varices: Severe PHG is more common in patients with esophageal varices 
than patients without varices. It also, correlated positively with the size of varices; denot‐
ing, it was higher in those with large varices than in those with medium‐sized or small 
varices [12].
• Location of varices: PHG was more commonly seen in patients with coexisting gastric and 
esophageal varices than in patients with only esophageal varices. Additionally, moderate 
or severe PHG was noted to be higher (not to a significant level) in patients with common 
collateral circulation vs uncommon collaterals. Portosystemic common collateral circula‐
tion includes esophageal varices, gastric varices, and vein dilatation (whether abdominal, 
umbilical, or hemorrhoid), while uncommon collaterals include splenorenal, gastric, renal, 
retroperitoneal, or cardiac angle venous shunts [14].
• Portal vein diameter: It was proposed that PHG is promoted by minimal collateral cir‐
culation since significant collaterals would otherwise reduce portal hypertension and 
gastric mucosal congestion. Later on, it was found that portal vein diameter in cirrhotic 
patients with PHG and no esophageal varices is greater than the portal vein diameter 
in patients with esophageal varices. This concept was further supported by the finding 
that patients with portal vein diameter < 12 mm have a significantly higher prevalence of 
esophageal varices than patients with larger portal vein diameter. It was then believed 
that the absence of reversed blood flow in the portal vein (due to the absence of hepatofu‐
gal flow), in patients without esophageal varices, meant that the pressure in the portal 
vein was not affected [15].
• Esophageal variceal eradication: PHG may appear for the first time in patients with portal 
hypertension, or increase in severity in patients with pre‐exciting PHG after eradication 
of esophageal varices by either endoscopic variceal ligation or endoscopic variceal sclero‐
therapy [16], thus patients with well developed fundal varices are more liable to develop 
PHG after obliteration of the varices than patients with poorly developed fundal varices. 
Since fundal varices are usually formed by a gastro‐renal shunt, this finding supports the 
view that the presence of a gastro‐renal shunt may play a protective role in the develop‐
ment of PHG after variceal obliteration. Therefore; some patients may exhibit minimum or 
no change in PHG after esophageal eradication [17].
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Other techniques are also used for obliteration of the esophageal varices including angio‐
graphic variceal obliteration (which increases the PHG frequency), and percutaneous trans‐
hepatic variceal embolization; after which 38% of the patients develop De‐novo PHG. The 
development of PHG for the first time or its increase in frequency and/or its severity is 
attributed to increased gastric mucosal congestion due to a decrease in the blood flow in the 
esophageal varices, which leads to an increase in the portal blood flow.
This phenomenon can be explained by obliteration of the blood flow after eradication of 
esophageal varices, this can lead to increased portal pressure and redistribution of residual 
blood flow that had passed through the previously patent varices. This mechanism is sup‐
ported by the finding that gastric mucosal blood flow increases after variceal ligation [4].
Some investigators believe that the higher rate of PHG in patients undergoing endoscopic 
variceal eradication (sclerotherapy or banding) merely reflects other factors rather than the 
procedures per se, factors like; increased duration of portal hypertension, advanced liver 
disease, or severe portal hypertension in patients selected to undergo variceal eradication, 
must be evaluated in patients who developed PHG or showed an increase in its severity 
[18]. Nevertheless, higher frequency of PHG in patients undergoing sclerotherapy, suggest 
that portal hypertension is still the main underlying cause of PHG
5.2. Factors related to liver cirrhosis
• Cirrhotic vs non‐cirrhotic portal hypertension: Primary liver disease usually occurs in 
PHG, but is not essential for PHG, provided another cause of portal hypertension exists. 
Consequently, PHG can occur in patients with other causes of portal hypertension; non‐
cirrhotic portal fibrosis, pre‐hepatic or post‐hepatic portal hypertension [19].
Portal pressure is not the only factor that is determinant of PHG, other factors, like cirrhosis, 
may be implicated in the development of the mucosal lesions, which are characteristic of PHG. 
PHG was found to occur more commonly in patients with cirrhotic liver than in non‐cirrhotic 
portal hypertension patients, also the patients with cirrhosis have a more aggressive course of 
PHG with faster progression to more severe PHG as time advances [19].
Taking this in consideration, other factors may also be involved in the pathogenesis of PHG. 
For example, in patients with portal hypertension and cirrhosis, there is an increase in the 
level of many vasodilator substances in systemic circulation e.g. gastrin, secretin, and VIP, 
this increase in the level of vasodilator or the decrease in the sensitivity to vasoconstrictor 
substance may have a role in the underlying mechanism of PHG [10]. However, these changes 
were also found in cirrhotic patients not suffering from PHG, thus the exact picture of the 
pathogenesis is not yet fully understood.
• Duration of liver disease: The duration of liver disease positively correlates with develop‐
ment of PHG, with average cumulative incidence of 3% at 1 year, 10% at 2 years, and 24% 
at 3 years [7].
• Liver disease severity: PHG is correlated with liver disease severity, as measured by Child‐
Turcotte‐Pugh score (CTP score) (Table 2), Child‐Pugh stage C cirrhosis is associated with 
more frequent and faster progression of PHG. Also, it was found that cirrhotic patients 
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with severe PHG (especially those without esophageal varices) had more frequent CTP 
stage C than patients with mild PHG [7].
Model for end‐stage liver disease (MELD) is another important scoring system for 
assessing liver disease severity, which was found to significantly correlate with PHG 
severity [20].
On the other hand, the severity of PHG was correlated to markers of advanced liver disease 
(like hypoalbuminemia and hyperbilirubinemia) which are biochemical markers of advanced 
liver disease. Markers of portal hypertension (thrombocytopenia) and of insulin resistance 
(hyperglycemia), were also significant independent predictors of PHG [21].
5.3. Other factors
Many other factors may be involved in the pathogenesis of PHG, this includes thrombocyto‐
penia or splenomegaly which are associated with the severity of PHG. Additional factors like 
an increase in the thickness of the lesser omentum and the presence of a splenorenal shunt 
were found to correlate with PHG in patients with chronic liver disease [22].
5.3.1. Factors that do not affect the risk of PHG
Although, portal hypertension is essential for PHG diagnosis, there is still no association 
between the etiology of portal hypertension and PHG. Similarly, as cirrhosis is the common 
cause of portal hypertension, there is no correlation between the underlying causes of cirrho‐
sis and PHG. Moreover, in cirrhotic patients, the role of Helicobacter pylori (H. pylori) in the 
pathogenesis of PHG is not fully understood. Some contributed that Helicobacter has no role 
in the pathogenesis of PHG in these patients [23]. However, there is evidence of association 
between H. pylori infection and PHG in cirrhotic patients, in these patients, Helicobacter 
infection may be related to the severity of PHG. This was strengthened by the fact that there 
was mild improvement of PHG after H. pylori eradication. Therefore, we can conclude that 
there may be a minor role for H. pylori in the pathogenesis of PHG in cirrhotic patients [23]. 
Further studies on large number of patients are conducted to show the effect of H. pylori 
eradication in the treatment of PHG, especially severe portal gastropathy in cirrhosis.
Parameter Point assigned
1 2 3
Albumin (g/dl) >3.5 2.8–3.5 <2.8
Bilirubin (mg/dl) <2 2–3 >3
INR <1.7 1.7–2.3 >2.3
Ascites None Slight‐moderate Tense
Encephalopathy 0 1–2 3–4
A total Child‐Turcotte‐Pugh score of 5–6 considered class A, 7–9 is class B, and 10– 15 is class C. INR, international 
normalized ratio.
Table 2. Child‐Turcotte‐Pugh score.
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Also, there is no evidence that there is any increase in the prevalence or severity of PHG with 
the use of either nonsteroidal anti‐inflammatory drugs (NSAIDs), or COX‐(cyclooxygenase)‐2 
inhibitor [24]. Another negative correlation was found between alcohol and smoking along‐
side PHG, thus there is no benefit from abstinence or quitting smoking [25]. Likewise, the 
presence of PHG was independent of patient’s age, or sex.
6. Whom should go for screening for PHG
Patients with portal hypertension and chronic iron deficiency anemia who are suspected to 
have chronic bleeding should go for PHG screening. Chronic bleeding is diagnosed when 
there is either decrease in hemoglobin level below 2 g/dL within 6‐month, or if there is pres‐
ence of iron deficiency anemia with a positive fecal occult blood test. For those patients, upper 
endoscopy can confirm the diagnosis of PHG [26].
7. Natural history
PHG may change in an individual patient over time, about 30% of the patients with cirrhosis 
and mild PHG, progress to severe PHG during a 10 year follow up period, considering that 
these patients did not receive any prophylactic treatment. Most of the patients with worsening 
PHG, severe lesions, or de novo PHG develop bleeding. There are only a few improved cases 
in PHG without treatment [27]. Furthermore, Patients who have PHG associated with cirrho‐
sis‐related portal hypertension have more frequently persistent and progressive PHG, which 
is more likely to bleed than patients with PHG related to non‐cirrhotic portal hypertension [9].
Although, as mentioned above, patients with previous endoscopic therapy (sclerotherapy or 
endoscopic variceal ligation) have a higher prevalence of PHG, the clinical course of PHG in 
this context, particularly in non cirrhotic portal hypertension, may be milder and transient [28].
PHG is a dynamic condition emphasized by the observation that 30% of patients who have 
endoscopic features of PHG remained unchanged throughout follow‐up period, whereas 25% 
of patients show either worsening or improvement of the condition during the follow up 
period. Thus, not only can PHG appear for the first time or progress from mild to severe 
condition over time, but it can also revert from severe to mild, and even disappear completely 
with treatment [23].
8. Clinical picture
Most patients with PHG are asymptomatic, but a significant number of patients exhibit symp‐
toms related to iron deficiency anemia from chronic GI bleeding. Bleeding from PHG may 
be either chronic occult blood in the stool, or overt which occurs in a smaller proportion of 
patients. Endoscopic diagnosis of acute hemorrhage from PHG is established when there is 
active bleeding from gastropathy lesions, if non‐removable clots overlying these lesions is 
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observed, or when there is PHG and no other cause of acute bleeding can be demonstrated 
after thorough evaluation of the gastrointestinal tract [9]. Recurrent bleeding is common in 
PHG after the initial episode.
Although all PHG patients with chronic bleeding develop severe chronic iron deficiency ane‐
mia, no study has evaluated the prevalence of PHG in cirrhotic patients with chronic iron 
deficiency anemia. In patients with portal hypertension, with or without cirrhosis and chronic 
iron deficiency anemia, chronic bleeding from PHG must be suspected, its diagnosis is con‐
firmed by upper endoscopy. Comprehensive study of the whole gastrointestinal tract in these 
patients by capsule endoscopy is mandatory to exclude similar lesion elsewhere along gastro‐
intestinal tract e.g. colonopathy [27].
8.1. Diagnosis
The diagnosis of PHG is done mainly by upper endoscopy. The endoscopic findings of 
PHG diagnosis was classified by the New Italian Endoscopic Club according to its severity 
based on the presence of four elementary lesions: mosaic like pattern, red point lesions, 
cherry red spots, and black brown spots (Figure 1) [29]. Early change in PHG is called 
scarletina, which appears as a fine pink speckling. On the other side, severe PHG appear as 
cherry red spots that may become confluent and is very friable, so it can actively bleed dur‐
ing endoscopy. These lesions are present predominantly in the fundus and/or the corpus of 
the stomach, yet PHG–like lesions have been described in other sites in the gastrointestinal 
tract e.g. the rectum, colon, and small bowel in asymptomatic patients and in patients with 
bleeding [29].
8.2. Endoscopic evaluation of PHG
The elementary lesions of PHG according to the New Italian Endoscopic Club for the Study 
and Therapy of Esophageal Varices [NIEC] classification are as follows [30]:
(1) Mosaic‐like pattern (MLP); it is described as the presence of small, polygonal areas in the 
center (areola) surrounded by a whitish‐yellow depressed border. The term mosaic is 
further subdivided according to the color of the areola into; mild, when the areola is uni‐
formly pink, moderate, if the center is red, and severe, when the areola is uniformly red.
(2) Red‐point lesions (RPLs) are defined as red, small, flat lesions, and <1 mm in size.
(3) Cherry‐red spots (CRSs) are defined as red, round lesions, >2 mm in diameter, which 
slightly protrude into the lumen of the stomach.
(4) Black‐brown spots (BBSs) are defined as irregularly flat spots, either black or brown in 
color, does not disappear after washing, and it is due to intra‐mucosal hemorrhage.
PHG is classified by endoscopy, into mild, moderate and severe forms. PHG mucosa can be 
seen as snakeskin (MLP) in mild cases, while RPLs, CRSs or BBCs that is liable to bleeding, 
are found in severe cases, however, the presence of red or brown spots without bleeding is 
considered a moderate disease [35].
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8.3. Classification of portal hypertensive gastropathy
PHG is classified on the basis of the condition’s severity, therefore many classifications of the 
PHG mucosa have been proposed. McCormack’s classification, NIEC’s and Tanoue’s classifi‐
cations are the most popular used classifications (Table 3). McCormack classified the mucosal 
changes into two main categories, mild and severe, on the other hand, the NIEC classification 
has three categories; mild, moderate and severe, and further subdivided the mosaic‐like pat‐
tern into three groups [28]. Finally, the McCormack classification, a two‐category classifica‐
tion system, is the recommended one. The classification comprises of:
Mild portal hypertensive gastropathy: Only one change in the stomach mucosa is present, 
that of appearance of mosaic or snakeskin pattern on it.
Figure 1. Endoscopic images of portal hypertensive gastropathy that show the four main findings of this condition. Mild 
(A) and moderate (B) mosaic‐like gastric mucosal pattern, red point lesions (C), cherry‐red spots (D), and black–brown 
spots, including an intramucosal hemorrhage (E) and a brown spot (F).
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Severe portal hypertensive gastropathy: In addition to the mosaic or snakeskin pattern of the 
stomach mucosa; bulging, flat red or black‐brown spots are seen. There also may be active 
bleeding.
In the rare instance where PHG cannot be clearly diagnosed on the basis of endoscopic 
appearance and location alone, biopsy for histology may prove useful [28].
8.4. Histologically
The unique histological features of PHG are marked dilatation of the capillaries and collect‐
ing venules in the gastric mucosa with markedly congested and tortuous submucosal venules 
(Figure 2) [31]. These vascular features are present in the absence of any inflammatory cell 
Figure 2. Hematoxylin and eosin shows numerous dilated capillaries in the superfacial gastric mucosa. These are not 
entirely specific for PHG.
McCormack NIEC Tanoue
Mild Scarlatina type rash
Snake skin Pink in center mosaic Mild redness
Striped appearance
Moderate – Flat red spots mosaic Fine red speckling mosaic
Severe Red spots Diffusely red mosaic Point bleeding
Diffuse hemorrhagic 
lesions
Table 3. Endoscopic finding and classification of PHG.
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infiltrate or erosion of the gastric mucosa. Stromal fibrosis and edema of the lamina propria 
can also be seen [31].
It may be difficult to differentiate between severe PHG and gastric antral vascular ectasia 
(GAVE) by endoscopic examination, so biopsy is beneficial in this case, as GAVE has distinct 
histological features that can set it apart from severe PHG. GAVE has many fibrin thrombi in 
the mucosal vessels with ectasia and spindle cell proliferation (smooth muscle and myofibro‐
blast hyperplasia) in the superficial mucosa. Furthermore, fibrohyalinosis is more commonly 
present in GAVE. All of these findings provide additional features that help in differentiating 
between severe PHG and GAVE [32].
8.5. Portal gastropathy score calculation
Table 4 shows the scoring system to calculate the severity of PHG, the calculation depends 
on three categories: Microscopic picture; score 1 considered for mild findings, and score 2 
for severe findings. Red marks; isolated lesion is considered score 1, whereas confluent red 
marks is scored 2. GAVE; if absent scored 0, while its presence is scored 2. If the total score 
was equal to 3 or less, the PHG is mild, on the other hand if the score is 4 or greater, PHG is 
severe [33].
8.6. Other diagnostic modalities
8.6.1. Non‐endoscopic methods for diagnosis of HPG
Other non‐endoscopic methods for the diagnosis of PHG such as MRI and CT are not yet 
considered as routine investigation for the diagnosis of PHG. Their results must be further 
evaluated to warrant their role in the diagnosis of PHG. Endoscopy still remains the main 
diagnostic method [34].
In CT scan, enhancement of the inner layer of the gastric walls due to gastric congestion, char‐
acterizes PHG lesion. Similarly, MRI is used to measure the diameter of collateral veins e.g. the 
left gastric, paraesophageal, and azygos veins to confirm the diagnosis of portal hypertension. In 
patients with PHG, the measurement of the diameters of these veins does not differ from those 
Endoscopic findings Parameter Score
Mucosal mosaic pattern Mild 1
Severe 2
Red markings Isolated 1
Confluent 2
Gastric antral vascular ectasia 
(GAVE)
Absence 1
Presence 2
Mild portal hypertensive gastropathy ≤ 3; severe portal hypertensive gastropathy ≥ 4.
Table 4. Portal hypertensive Gastropathy scoring system.
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in patients without PHG, therefore it is not helpful in the diagnosis. These data suggest that these 
imaging techniques is still in its infancy period and best reserved for experimental purposes [35].
8.7. Differential diagnosis
The endoscopic findings of the gastric mucosa include many differential diagnoses of several 
disorders. When red spots are seen in the stomach by endoscopy, important diagnostic con‐
siderations are evoked. GAVE or watermelon stomach which is a common differential diag‐
nosis of PHG, has characteristic endoscopic findings which are linear red stripes, separated 
by normal mucosa, these findings give the appearance of a watermelon, that is seen in the 
gastric antrum or proximal stomach. GAVE and PHG are distinct entities, however both are 
encountered in cirrhotic patients. While PHG routinely affects the gastric body and fundus, 
GAVE almost exclusively inhabits the antrum [32].
These findings have a diagnostic accuracy of 85% for GAVE and help distinguish it from PHG.
Table 5 further shows the differences between GAVE and PHG, however, there may be an 
overlap between GAVE and PHG in cirrhosis with portal hypertension [6].
Other conditions that increase the dilemma of PHG diagnosis include simple acute gastritis 
caused by non‐steroidal anti–inflammatory drug (NSAIDS) or H. pylori, which may have a 
mosaic like pattern endoscopically but, the main histopathological feature in gastritis is inflam‐
matory cell infiltration with minor vascular dilation, and it is also localized to the mucosa 
(superficial lesion). Lastly, endoscopic lesions similar to PHG may be also seen in some uncom‐
mon diseases e.g. polycythemia, gastric purpura, and Osler‐Weber‐Rendu disease [36].
PHG GAVE
Underlying etiology Portal hypertension with or without cirrhosis Can be present without portal hypertension, 
such as chronic renal failure, connective tissue 
disorders, and bone marrow transplantation
Predominant location Fundus and corpus Antrum
Endoscopic appearance Mosaic like pattern or red marks Linear red strips separated by normal mucosa
Pathological findings Dilatation of the capillaries, and collecting 
venules in the gastric mucosa. Ectasia of 
submucosal veins, with intimal thickening
Fibrin microthrombi, myofibroplast 
hyperplasia, fibrinolysis
Management
• Response to beta 
blockers
Yes No
• TIPS Yes No
• Endoscopic therapy 
ACP
Used in refractory bleeding Preferable as first line
ACP, argon plasma coagulation.
Table 5. Comparison between portal hypertensive gastropathy and gastric antral vascular ectasia.
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9. Management of PHG
The goal of management of PHG is to reduce portal pressure.
9.1. Primary prophylaxis
PHG in asymptomatic patients who have no evidence of bleeding is discovered accidentally 
during screening for either chronic iron deficiency anemia or for esophageal varices in patients 
with cirrhosis. Till now, there is no recommendation to start any primary prophylaxis to pre‐
vent bleeding from PHG patients, except if there is an indication of beta‐blocker for other rea‐
sons. However, in asymptomatic patients with both esophageal varices and PHG, if the patient 
undergoes esophageal eradication therapy, co‐administration of a nonselective beta‐blocker is 
beneficial. The dose of beta blocker should be titrated to a goal heart rate of 55–60 bpm or a 
25% reduction from baseline. On the other hand, in patients with severe PHG and no varices, 
starting prophylaxis therapy with nonselective beta‐blockers, should be considered. Yet, this 
approach is controversial, and more research is needed to clarify the prophylactic role of beta‐
blockers as primary prophylaxis for bleeding from PHG [34].
9.2. Secondary prophylaxis
Beta‐blockers (like propranolol or nadolol) are used as secondary prophylaxis, and are the basis 
of therapy, to prevent recurrent bleeding from PHG. It is not only used to prevent the bleeding, 
but it also improves the severity score of PHG by endoscopy, changing it from severe to mild, or 
even completely curing it. On the other hand, about 50% of PHG patients especially cirrhotic dur‐
ing a 2‐year follow up, show mild or even no response to beta blocker therapy. For those patients 
adding isosorbide 5‐mononitrate may have a synergistic effect to reduce the portal pressure [37].
Addition of beta‐blocker therapy to endoscopic management of varices is beneficial in reduc‐
ing the progression of PHG after endoscopic therapy of varices. Propranolol, a non‐selective 
beta‐blocker (24–480 mg/day), has been commonly used in these cases. The dose of proprano‐
lol should be increased gradually to maximum dose (up to 160 mg twice daily) with targeted 
heart rate of 55–60 bpm, and should be continued as long as there is portal hypertension [37]. 
In patients with iron deficiency anemia, iron replacement therapy and beta blocker should be 
started simultaneously.
9.3. Treatment of chronic bleeding
Patients with PHG with or without cirrhosis, and chronic blood loss are commonly presented 
with iron deficiency anemia. Thorough investigation of these patients must be done to rule 
out other causes of iron deficiency anemia before attributing PHG as the cause. All patients 
with PHG and iron deficiency anemia should start iron‐replacement therapy either; oral prep‐
arations, or intravenous (IV) iron.
To reduce chronic bleeding from PHG, with or without portal hypertension, portal pressure 
should be reduced, therefore non selective beta blocker is the first line of treatment. The use 
of beta blockers has proved efficient, based on both experimental and clinical investigations 
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demonstrating that, propranolol reduces portal pressure and cause vasoconstriction in the 
overall splanchnic vascular bed.
Anti‐oxidants have also been used to treat PHG. Experimentally, Vitamin E led to complete 
reversal of susceptibility of PHG mucosa to alcohol injury, in rats. Vitamin E also, led to the 
restoration of normal Extracellular signal‐regulated kinase (ERK‐2 signaling), which plays 
a pivotal role in healing after gastric mucosal injury. Thus, vitamin E may have a protective 
effect on the PHG mucosa [38].
Use of other pharmacological agents such as losartan, thalidomide and corticosteroids have 
been prescribed in the treatment of chronic bleeding from PHG. However, the evidence sup‐
porting their use in PHG bleeding is weak [39].
9.4. Treatment of acute bleeding
• For acute bleeding; initial stabilization with octreotide or terlipressin to stop the bleeding, 
followed by initiation of beta‐blockers as secondary prevention is recommended. During 
acute bleeding from PHG, the patients may be hemodynamically unstable, therefore beta 
blocker therapy must be reserved, regarding its drawback, as it has a negative effect on 
heart and the circulation. Despite the drawbacks of beta‐blocker therapy, it is considered 
immediately after the patient becomes hemodynamically stable, usually within 3 days. This 
highlights their important role in the management of acute as well as chronic GI bleeding.
• Octreotide, a somatostatin analogue (100 μg bolus followed by an infusion of 25 μg/h for 
48 h), and Terlipressin, a vasopressin analogue, are both effective in the treatment of acute 
bleeding caused by PHG. Vasopressin and omeprazole when used together are more effec‐
tive in controlling the acute bleeding than when vasopressin is used alone [40].
9.5. For refractory cases
When the patients do not respond to the previously mentioned treatments, invasive interven‐
tion must be done. Transjugular intrahepatic portosystemic shunt (TIPS) or surgical shunt are 
considered as salvage therapy only when they are performed in certain circumstances and in 
an expert center due to their significant morbidity and mortality results [41].
Surgical shunting has also proved beneficial in refractory bleeding from PHG however, this 
benefit is limited by an increase in the risk of deterioration of the hepatic function in patients 
with cirrhosis. Only cirrhotic patients with Child Pugh score A or B found improved out‐
comes from surgical shunting with reduced mortality. Comparing the results of TIPS with 
surgical shunt, it is reported that surgical shunt reduced re‐bleeding, with fewer shunt 
complication e.g. shunt revisions, stent thrombosis, re‐stenosis, and re‐intervention of 
TIPS. However, long‐term mortality was similar. On the other hand, similar results were 
found between TIPSS and distal splenorenal shunting with regards to re‐bleeding, enceph‐
alopathy, and survival. Whatever the method of shunting in case of refractory bleeding 
from PHG, it should always be performed in expertise center. Surgical shunting may be 
an option only in CTP stage A cirrhosis with PHG or in patients with non‐cirrhotic portal 
hypertension [42].
Portal Hypertensive Gastropathy (PHG)
http://dx.doi.org/10.5772/intechopen.69539
71
Argon plasma coagulation (APC) is an electrosurgical technique used for treatment of bleed‐
ing of PHG. APC is a noncontact thermal coagulation, high frequency current, that is applied 
to the bleeding site through an argon plasma jet, this creates effective hemostasis and a homog‐
enous surface coagulation with limited depth penetration. Treatment with APC decrease the 
need of transformation and improve the hemoglobin level in PHG patients, accordingly APC 
is an effective and rapid therapy to control bleeding from PHG, especially if there is a con‐
traindication for beta blockers. If beta blocker can be used, co administration with APC has a 
synergistic effect in controlling PHG bleeding [5].
Hemospray: In patients with acute active bleeding due to PHG, it may be useful to use hemo‐
static powder that acts as a barrier to enhance the action of the clotting factors, giving time for 
the coagulation process to act and stop the bleeding [43]. A treatment algorithm for patients 
with PHG is described in Figure 3.
10. Mortality rates
Limited data on mortality due to bleeding from PHG is available, but the bleeding from PHG 
is rarely fatal. It represents a small percentage if compared with the mortality from other 
causes of gastrointestinal bleeding due to portal hypertension, and especially in comparison 
Figure 3. Treatment algorithm of portal hypertensive gastropathy.
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to variceal bleeding. Also, in cirrhotic patients it represents only <1% of the mortality, because 
the bleeding is typically mild [4]. As bleeding from PHG is an unusual direct cause of death, 
it does not affect the survival in cirrhotic patients. However, anemia from chronic bleeding or 
repeated acute bleeding may lead to deterioration of the liver function.
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